The company posted revenue of Rs. 703 crore in Q4 FY26
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
The base Gland business posted ?11,790 million in revenue, up 16% YoY
The company’s revenue stood at Rs. 287.68 crore, reflecting a 4.7 percent increase over Rs. 274.71 crore reported in FY25
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
Profit after tax took a sharp hit, falling to Rs. 33 Cr in Q4 FY26, down from Rs. 106 Cr in Q4 FY25 and Rs. 52 Cr in Q3 FY26
The company reported free cash flow of Rs. 2,590 Mn for FY26
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Subscribe To Our Newsletter & Stay Updated